Topic: How To Invest

Please provide an opinion on Inspire Pharmaceuticals (ISPH). I realize that it is speculative.

Article Excerpt

Inspire Pharmaceuticals Inc., $6.99, symbol ISPH on Nasdaq (Shares outstanding: 82.8 million; Market cap: $578.9 million; www.inspirepharm.com) develops and markets drugs for various eye and respiratory diseases, usually with other drug companies, such as Allergan Inc. (symbol AGN on New York) and InSite Vision Inc. (symbol INSV on Nasdaq OTC). Based in Durham, North Carolina, Inspire began operating in March 1995. The company first sold shares to the public for $12.00 each, and began trading on Nasdaq on August 3, 2000. The company’s main products are AzaSite and Elestat, which treat eye infections, and Restasis, a treatment for dry-eye disease. A second dry-eye drug, Diquas, recently received approval from Japanese drug regulators. In the three months ended September 30, 2010, Inspire’s revenue rose 6.2%, to $26.7 million from $16.1 million a year earlier. Higher revenue from AzaSite and Restasis offset a lower contribution from Elestat. The company lost $7.6 million, or $0.09 a share. That’s an improvement over the $8.5 million, or…